# Lisata Therapeutics, Inc.: financial statements, quarterly

LSTA · Nasdaq · CIK 320017 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lsta.md) · [Financials](/companies/lsta/financials.md) · [Filings](/companies/lsta/filings.md) · [Insiders](/companies/lsta/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lsta/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [0.0](/filings/0000320017-24-000058.md) | [0.0 d](/filings/0000320017-25-000011.md) | [0.0](/filings/0000320017-25-000030.md) | [0.0](/filings/0000320017-25-000060.md) | [0.0](/filings/0000320017-25-000070.md) | [1,000 d](/filings/0000320017-26-000023.md) | [0.0](/filings/0000320017-26-000032.md) | [70.0](/filings/0000320017-26-000038.md) | [0.0](/filings/0000320017-25-000070.md) | [100 d](/filings/0000320017-26-000023.md) | [0.0](/filings/0000320017-26-000032.md) | [0.0](/filings/0000320017-26-000038.md) |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $k | [2,584](/filings/0000320017-24-000058.md) | [3,012 d](/filings/0000320017-24-000007.md) | [3,360](/filings/0000320017-25-000030.md) | [2,922](/filings/0000320017-25-000060.md) | [2,794](/filings/0000320017-25-000070.md) | not reported | [3,245](/filings/0000320017-25-000030.md) | [2,685](/filings/0000320017-25-000060.md) | [2,455](/filings/0000320017-25-000070.md) | not reported | not reported | not reported |
| Operating income | $k | [(5,964)](/filings/0000320017-24-000058.md) | [(6,025) d](/filings/0000320017-25-000011.md) | [(6,601)](/filings/0000320017-25-000030.md) | [(5,523)](/filings/0000320017-25-000060.md) | [(5,336)](/filings/0000320017-25-000070.md) | [(4,949) d](/filings/0000320017-26-000023.md) | [(5,847)](/filings/0000320017-26-000032.md) | [(4,868)](/filings/0000320017-26-000038.md) | [(4,414)](/filings/0000320017-25-000070.md) | [(3,079) d](/filings/0000320017-26-000023.md) | [(4,942)](/filings/0000320017-26-000032.md) | [(3,992)](/filings/0000320017-26-000038.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [0.0](/filings/0000320017-24-000058.md) | [0.0 d](/filings/0000320017-25-000011.md) | [(798)](/filings/0000320017-25-000030.md) | [0.0](/filings/0000320017-25-000060.md) | [0.0](/filings/0000320017-25-000070.md) | [0.0 d](/filings/0000320017-26-000023.md) | [(962)](/filings/0000320017-26-000032.md) | [0.0](/filings/0000320017-26-000038.md) | [0.0](/filings/0000320017-25-000070.md) | [0.0 d](/filings/0000320017-26-000023.md) | [(387)](/filings/0000320017-26-000032.md) | [0.0](/filings/0000320017-26-000038.md) |
| Net income | $k | [(5,261)](/filings/0000320017-24-000058.md) | [(5,365) d](/filings/0000320017-25-000011.md) | [(5,401)](/filings/0000320017-25-000030.md) | [(5,044)](/filings/0000320017-25-000060.md) | [(4,930)](/filings/0000320017-25-000070.md) | [(4,610) d](/filings/0000320017-26-000023.md) | [(4,724)](/filings/0000320017-26-000032.md) | [(4,659)](/filings/0000320017-26-000038.md) | [(4,249)](/filings/0000320017-25-000070.md) | [(2,954) d](/filings/0000320017-26-000023.md) | [(4,489)](/filings/0000320017-26-000032.md) | [(2,929)](/filings/0000320017-26-000038.md) |
| Diluted EPS | $ per share | [(0.65)](/filings/0000320017-24-000058.md) | not reported | [(0.65)](/filings/0000320017-25-000030.md) | [(0.61)](/filings/0000320017-25-000060.md) | [(0.59)](/filings/0000320017-25-000070.md) | not reported | [(0.55)](/filings/0000320017-26-000032.md) | [(0.54)](/filings/0000320017-26-000038.md) | [(0.49)](/filings/0000320017-25-000070.md) | not reported | [(0.50)](/filings/0000320017-26-000032.md) | [(0.32)](/filings/0000320017-26-000038.md) |
| Basic EPS | $ per share | [(0.65)](/filings/0000320017-24-000058.md) | not reported | [(0.65)](/filings/0000320017-25-000030.md) | [(0.61)](/filings/0000320017-25-000060.md) | [(0.59)](/filings/0000320017-25-000070.md) | not reported | [(0.55)](/filings/0000320017-26-000032.md) | [(0.54)](/filings/0000320017-26-000038.md) | [(0.49)](/filings/0000320017-25-000070.md) | not reported | [(0.50)](/filings/0000320017-26-000032.md) | [(0.32)](/filings/0000320017-26-000038.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [32.4](/filings/0000320017-23-000063.md) | [22.6](/filings/0000320017-25-000011.md) | [21.8](/filings/0000320017-24-000031.md) | [28.3](/filings/0000320017-24-000051.md) | [19.5](/filings/0000320017-24-000058.md) | [16.2](/filings/0000320017-26-000023.md) | [20.2](/filings/0000320017-25-000030.md) | [16.8](/filings/0000320017-25-000060.md) | [19.0](/filings/0000320017-25-000070.md) | [16.0](/filings/0000320017-26-000038.md) | [13.1](/filings/0000320017-26-000032.md) | [10.4](/filings/0000320017-26-000038.md) |
| Current assets | $m | [57.2](/filings/0000320017-23-000063.md) | [53.9](/filings/0000320017-25-000011.md) | [47.6](/filings/0000320017-24-000031.md) | [42.0](/filings/0000320017-24-000051.md) | [37.7](/filings/0000320017-24-000058.md) | [34.6](/filings/0000320017-26-000023.md) | [28.6](/filings/0000320017-25-000030.md) | [24.9](/filings/0000320017-25-000060.md) | [21.6](/filings/0000320017-25-000070.md) | [17.7](/filings/0000320017-26-000038.md) | [14.0](/filings/0000320017-26-000032.md) | [11.0](/filings/0000320017-26-000038.md) |
| Total assets | $m | [58.1](/filings/0000320017-23-000063.md) | [54.7](/filings/0000320017-25-000011.md) | [48.2](/filings/0000320017-24-000031.md) | [42.6](/filings/0000320017-24-000051.md) | [38.2](/filings/0000320017-24-000058.md) | [35.0](/filings/0000320017-26-000023.md) | [29.0](/filings/0000320017-25-000030.md) | [25.2](/filings/0000320017-25-000060.md) | [21.8](/filings/0000320017-25-000070.md) | [17.7](/filings/0000320017-26-000038.md) | [14.1](/filings/0000320017-26-000032.md) | [11.0](/filings/0000320017-26-000038.md) |
| Current liabilities | $m | [5.1](/filings/0000320017-23-000063.md) | [6.6](/filings/0000320017-25-000011.md) | [5.3](/filings/0000320017-24-000031.md) | [4.5](/filings/0000320017-24-000051.md) | [4.7](/filings/0000320017-24-000058.md) | [5.6](/filings/0000320017-26-000023.md) | [3.8](/filings/0000320017-25-000030.md) | [4.3](/filings/0000320017-25-000060.md) | [4.6](/filings/0000320017-25-000070.md) | [3.1](/filings/0000320017-26-000038.md) | [3.3](/filings/0000320017-26-000032.md) | [3.0](/filings/0000320017-26-000038.md) |
| Total liabilities | $m | [5.4](/filings/0000320017-23-000063.md) | [6.8](/filings/0000320017-25-000011.md) | [5.5](/filings/0000320017-24-000031.md) | [4.6](/filings/0000320017-24-000051.md) | [4.8](/filings/0000320017-24-000058.md) | [5.7](/filings/0000320017-26-000023.md) | [3.9](/filings/0000320017-25-000030.md) | [4.4](/filings/0000320017-25-000060.md) | [4.6](/filings/0000320017-25-000070.md) | [3.1](/filings/0000320017-26-000038.md) | [3.4](/filings/0000320017-26-000032.md) | [3.0](/filings/0000320017-26-000038.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [53.0](/filings/0000320017-23-000063.md) | [48.1](/filings/0000320017-25-000011.md) | [43.0](/filings/0000320017-24-000031.md) | [38.2](/filings/0000320017-24-000051.md) | [33.7](/filings/0000320017-24-000058.md) | [29.6](/filings/0000320017-26-000023.md) | [25.4](/filings/0000320017-25-000030.md) | [21.0](/filings/0000320017-25-000060.md) | [17.4](/filings/0000320017-25-000070.md) | [14.9](/filings/0000320017-26-000038.md) | [10.9](/filings/0000320017-26-000032.md) | [8.2](/filings/0000320017-26-000038.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,583) d](/filings/0000320017-24-000058.md) | [(4,069) d](/filings/0000320017-25-000011.md) | [(7,027)](/filings/0000320017-25-000030.md) | [(5,283) d](/filings/0000320017-25-000060.md) | [(2,518) d](/filings/0000320017-25-000070.md) | [(4,528) d](/filings/0000320017-26-000023.md) | [(5,402)](/filings/0000320017-26-000032.md) | [(3,956) d](/filings/0000320017-26-000038.md) | [(3,342) d](/filings/0000320017-25-000070.md) | [(3,249) d](/filings/0000320017-26-000023.md) | [(3,083)](/filings/0000320017-26-000032.md) | [(2,649) d](/filings/0000320017-26-000038.md) |
| Capital expenditure | $k | [0.0 d](/filings/0000320017-23-000063.md) | [0.0 d](/filings/0000320017-24-000007.md) | [0.0](/filings/0000320017-25-000030.md) | [0.0 d](/filings/0000320017-25-000060.md) | [0.0 d](/filings/0000320017-25-000070.md) | [0.0 d](/filings/0000320017-26-000023.md) | [28.0](/filings/0000320017-26-000032.md) | [0.0 d](/filings/0000320017-26-000038.md) | [0.0 d](/filings/0000320017-25-000070.md) | [0.0 d](/filings/0000320017-26-000023.md) | [0.0](/filings/0000320017-26-000032.md) | [0.0 d](/filings/0000320017-26-000038.md) |
| Dividends paid | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [4,747](/filings/0000320017-23-000063.md) | [7,987](/filings/0000320017-24-000031.md) | [8,021](/filings/0000320017-24-000051.md) | [8,141](/filings/0000320017-24-000058.md) | [8,294](/filings/0000320017-25-000030.md) | [8,308](/filings/0000320017-25-000060.md) | [8,321](/filings/0000320017-25-000070.md) | [8,602](/filings/0000320017-26-000032.md) | [8,605](/filings/0000320017-26-000038.md) | [8,738](/filings/0000320017-25-000070.md) | [9,006](/filings/0000320017-26-000032.md) | [9,106](/filings/0000320017-26-000038.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 9,010,937 at 2026-08-06, from the cover of the [10-Q filed 2026-08-06](/filings/0000320017-26-000038.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.